iCAD and Sectra partner on distribution for ProFound AI

por John R. Fischer, Senior Reporter | June 11, 2021
Artificial Intelligence Health IT Women's Health
ProFound AI (pictured here) and ProFound AI Risk are now available for sale on the Sectra Amplifier Marketplace
The Sectra Amplifier Marketplace will now supply iCAD’s ProFound AI and ProFound AI Risk platforms as part of a new distribution agreement between the two imaging providers, worldwide.

“With iCAD’s tools deeply embedded in the Sectra diagnostic workspace, we provide our radiologists with enhanced diagnostic confidence for breast imaging reading,” said Nynke Breimer, global product manager of AI Radiology at Sectra.

The Sectra Amplifier Marketplace was created to allow providers to have easier access to and usage of AI applications for medical imaging.

ProFound AI and ProFound AI Risk are deep learning based and expected to enable more accurate and personalized breast cancer screenings. Trained to detect malignant soft tissue densities and calcifications, ProFound AI for Digital Breast Tomosynthesis scored FDA clearance in December 2018 and became the first 3D tomosynthesis software with AI to do so. It is also available for 2D mammography.
DOTmed text ad

Reveal Mobi Pro now available for sale in the US

Reveal Mobi Pro integrates the Reveal 35C detector with SpectralDR technology into a modern mobile X-ray solution. Mobi Pro allows for simultaneous acquisition of conventional & dual-energy images with a single exposure. Contact us for a demo at no cost.


ProFound AI Version 3.0 for Digital Breast Tomosynthesis was cleared in March 2021, and offers up to a 10% improvement in specificity and up to 1% faster processing on the new PowerLook platform. It was developed using over five million images from 30,000 cases, including almost 8,000 biopsy-proven cancers.

ProFound AI Risk can provide a highly accurate short-term risk estimation specific to each woman by combining information from mammographic images with factors such as age and breast density. It provides a two-year breast cancer risk category of low, general, moderate, or high, and absolute breast cancer risk score for each patient, based on information from a standard bilateral two-view full-field digital mammogram. Its AUC of 0.73 in a recent study indicates high accuracy for risk assessment.

You Must Be Logged In To Post A Comment